HK1246209A1 - 環肌酸微混懸劑 - Google Patents

環肌酸微混懸劑

Info

Publication number
HK1246209A1
HK1246209A1 HK18105957.0A HK18105957A HK1246209A1 HK 1246209 A1 HK1246209 A1 HK 1246209A1 HK 18105957 A HK18105957 A HK 18105957A HK 1246209 A1 HK1246209 A1 HK 1246209A1
Authority
HK
Hong Kong
Prior art keywords
cyclocreatine
microsuspension
cyclocreatine microsuspension
Prior art date
Application number
HK18105957.0A
Other languages
English (en)
Inventor
H‧狄克遜
C‧J‧貝姆本
Original Assignee
盧莫斯製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 盧莫斯製藥公司 filed Critical 盧莫斯製藥公司
Publication of HK1246209A1 publication Critical patent/HK1246209A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK18105957.0A 2015-03-10 2018-05-08 環肌酸微混懸劑 HK1246209A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562130683P 2015-03-10 2015-03-10
PCT/US2016/021543 WO2016145067A1 (en) 2015-03-10 2016-03-09 Cyclocreatine microsuspension

Publications (1)

Publication Number Publication Date
HK1246209A1 true HK1246209A1 (zh) 2018-09-07

Family

ID=56879039

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18105957.0A HK1246209A1 (zh) 2015-03-10 2018-05-08 環肌酸微混懸劑

Country Status (8)

Country Link
US (1) US20180071261A1 (zh)
EP (1) EP3267997A4 (zh)
JP (1) JP2018511582A (zh)
CN (1) CN107427494A (zh)
AU (1) AU2016229111A1 (zh)
CA (1) CA2978322A1 (zh)
HK (1) HK1246209A1 (zh)
WO (1) WO2016145067A1 (zh)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0854712B1 (en) * 1995-10-11 2003-05-07 Avicena Group, Inc. Use of creatine analogues for the treatment of disorders of glucose metabolism
AU5636300A (en) * 1999-06-25 2001-01-31 Avicena Group, Inc. Use of creatine or creatine analogs for the prevention and treatment of transmissible spongiform encephalopathies
EP1567180A4 (en) * 2002-06-04 2010-03-10 Avicena Group Inc METHODS OF TREATING COGNITIVE DYSFUNCTIONS BY MODULATING BRAIN ENERGY METABOLISM
DE10244503A1 (de) * 2002-09-25 2004-04-08 Capsulution Nanoscience Ag Methode zur Herstellung und Stabilisierung von Mikro- und Nanosuspensionen mit Amphiphilen und Polyelektrolyten
CN1697648B (zh) * 2003-12-04 2010-06-23 辉瑞产品公司 减少了副作用的阿奇霉素剂型
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
ES2338039T3 (es) * 2005-04-13 2010-05-03 ABBOTT GMBH & CO. KG Procedimiento para la obtencion cuidadosa de supensiones de particulas de elevada finura y particulas de elevada finura, asi como su aplicacion.
AU2007249811A1 (en) * 2006-05-11 2007-11-22 Avicena Group, Inc. Creatine-ligand compounds and methods of use thereof
US8333987B2 (en) * 2008-11-11 2012-12-18 Elgebaly Salwa Nourexin-4 nano-lipid emulsions
GB201107308D0 (en) * 2011-05-03 2011-06-15 Gorman Edward O Oral rehydration products comprising creatine
US9233099B2 (en) * 2012-01-11 2016-01-12 University Of Cincinnati Methods of treating cognitive dysfunction by modulating brain energy metabolism

Also Published As

Publication number Publication date
CN107427494A (zh) 2017-12-01
AU2016229111A1 (en) 2017-09-21
CA2978322A1 (en) 2016-09-15
US20180071261A1 (en) 2018-03-15
JP2018511582A (ja) 2018-04-26
EP3267997A4 (en) 2018-08-15
WO2016145067A1 (en) 2016-09-15
EP3267997A1 (en) 2018-01-17

Similar Documents

Publication Publication Date Title
GB201707959D0 (en) No details
GB2538731B (en) Methods
GB201706130D0 (en) No details
GB201612542D0 (en) no details
GB201615071D0 (en) No details
GB201518762D0 (en) Methods
GB201709180D0 (en) No details
GB201517368D0 (en) Value
AU361999S (en) Ballustrade
GB201508927D0 (en) Methods
GB201616225D0 (en) No details
GB201601250D0 (en) No details present
GB201515655D0 (en) Methods
GB201708207D0 (en) No details
GB201702336D0 (en) No details
GB201511951D0 (en) An eyeguard
DK3242882T3 (en) Cgrp-antagonistpeptider
GB201512609D0 (en) Methods
HK1246209A1 (zh) 環肌酸微混懸劑
GB201614498D0 (en) No details
AU5516P (en) LEP08 Lepidosperma squamatum
PL69971Y1 (pl) Wkręt interferencyjny
AU5511P (en) PTK647 Epichloe coenophiala
GB201521840D0 (en) No details
AU366552S (en) Nutblock